DOG1 antibody in the differential diagnosis of gastrointestinal stromal tumors: A study of 1840 cases

American Journal of Surgical Pathology

Volumn 33, Issue 9, 2009, Pages 1401-1408

  Miettinen, Markku ^a   Wang, Zeng Feng ^a   Lasota, Jerzy ^a  

^a ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

Author keywords

Chloride channel protein; DOG1; Gastrointestinal stromal tumor; KIT; Mutation; PDGFRA; Sarcoma

Indexed keywords

DISCOVERED ON GASTROINTESTINAL STROMAL TUMOR 1; PLATELET DERIVED GROWTH FACTOR A; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR MARKER; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CLONE; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; EMBRYONIC STEM CELL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LEIOMYOMA; LEIOMYOMATOSIS; MAJOR CLINICAL STUDY; MESENCHYMOMA; MUTANT; MUTATION; SENSITIVITY AND SPECIFICITY; SPINDLE CELL; SQUAMOUS CELL CARCINOMA; STOMACH CARCINOMA; SYNOVIAL SARCOMA; THROMBOCYTE; UTERUS;

CARCINOMA, SQUAMOUS CELL; COLORECTAL NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; ESOPHAGEAL NEOPLASMS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL NEOPLASMS; LEIOMYOMA; MEMBRANE PROTEINS; MESENCHYMOMA; MYENTERIC PLEXUS; NEOPLASM PROTEINS; PERITONEAL NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS C-KIT; SARCOMA, SYNOVIAL; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 70249090434     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e3181a90e1a     Document Type: Article

References (33)

1. TM liquid mouse monoclonal antibody DOG-1. Novocastra Corporation, New Castle, UK.
2. Antonescu CR. Targeted therapies in gastrointestinal stromal tumors. Semin Diagn Pathol. 2008;25:295-303.
3. Blay P, Astudillo A, Buesa JM, et al. Protein kinase C theta is highly expressed in gastrointestinal stromal tumors but not in other mesenchymal neoplasias. Clin Cancer Res. 2004;10:4089-4095.
4. Caputo A, Caci E, Ferrera L, et al. TMEM16A, a membrane protein associated with calcium-dependent chloride channel activity. Science. 2008;322:590-594.
5. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813-3825.
6. Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23:5357-5364.
7. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472-480.
8. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet. 2006;368:1329-1338.
9. Dow N, Giblen G, Sobin LH. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol. 2006;23:111-119.
10. Duensing A, Joseph NE, Medeiros F, et al. Protein kinase C theta (PKC theta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res. 2004;64:5127-5131.
11. Espinosa I, Lee CH, Kim MK, et al. A novel monoclonal antibody against DOG1 is a sensitive and specific marker for gastrointestinal stromal tumors. Am J Surg Pathol. 2008;32:210-218.
12. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299: 708-710.
13. Kashyap MK, Marimuthu A, Kishore CJ, et al. Genomewide mRNA profiling of esophageal squamous cell carcinoma for identification of cancer biomarkers. Cancer Biol Ther. 2009;1:8.
14. Katoh M, Katoh M. FLJ10261 gene, located within the CCND1-EMS1 locus on human chromosome 11q13, encodes the eight-transmembrane protein homologous to C12orf3, C11 orf25 and FLJ34272 gene products. Int J Oncol. 2003;22:1375-1381.
15. Kindblom LG, Remotti HE, Aldenborg F, et al. Gastrointestinal pacemaker cell tumor (GIPACT). Gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;153:1259-1269.
16. Kitamura Y, Hirota S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci. 2004;61:2924-2931.
17. Lasota J, Dansonka-Meiszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors with low or no malignant potential. Lab Invest. 2004;84: 874-883.
18. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest. 2006;86:94-100.
19. Lasota J, Miettinen M. Clinical significance of oncogenic KIT and PDGFRA mutations in gastrointestinal stromal tumours. Histopathology. 2008;53:245-266.
20. Liegl B, Hornick JL, Corless CL, et al. Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors including unusual subtypes. Am J Surg Pathol. 2009;33:437-446.
21. Lucas DR, al-Abbadi M, Tabaczka P, et al. c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. Am J Clin Pathol. 2003;119:339-345.
22. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol. 2004;28:889-894.
23. Miettinen M, Lasota J. KIT (CD117): a review on expression in normal and neoplastic tissues, and mutations and their clinico-pathologic correlation. Appl Immunohistochem. 2005;13:205-220.
24. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic studies of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52-68.
25. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol. 2006;130:1466-1478.
26. Miettinen M, Makhlouf HR, Sobin LH, et al. Gastrointestinal stromal tumors (GISTs) of the jejunum and ileum-a clinicopatho-logic, immunohisto-chemical and molecular genetic study of 906 cases prior to imatinib with long-term follow-up. Am J Surg Pathol. 2006;30:477-489.
27. Motegi A, Sakurai S, Nakayama H, et al. PKC theta, a novel immunohistochemical marker for gastrointestinal stromal tumors (GIST), especially useful for identifying KIT-negative tumors. Pathol Int. 2005;55:106-112.
28. Sarlomo-Rikala M, Kovatich A, Barusevicius A, et al. CD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728-734.
29. Takazawa Y, Sakurai S, Sakuma Y, et al. Gastrointestinal stromal tumors of neurofibromatosis type I (von Recklinghausen?s disease). Am J Surg Pathol. 2005;29:755-763.
30. Wardelmann E, Hrychyk A, Merkelback-Bruse S, et al. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn. 2004;6:197-204.
31. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-113.
32. Yang YD, Cho H, Koo JY, et al. TMEM16A confers receptor-activated calcium-dependent chloride conductance. Nature. 2008; 455:1210-1215.
33. Yantiss RK, Spiro IJ, Compton CC, et al. Gastrointestinal stromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinically important differential diagnosis. Am J Surg Pathol. 2000; 24:947-957.